GlassScriptPhysician profile
Victor Maquera
NPI 1891786059
$25,854.26
in general payments reported to CMS, 2019-2025
71 companies · $4,897 in 2025
The $4,897 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,197 · 2020: $2,501 · 2021: $3,345 · 2022: $3,567 · 2023: $3,730 · 2024: $5,618 · 2025: $4,897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,956.26 |
| Education | $288.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,193.24 | 2021-2025 | |
| Biogen, INC. | $2,104.25 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Novartis Pharmaceuticals Corporation | $1,786.37 | 2019-2025 | |
| Eisai INC. | $1,366.42 | 2019-2025 | |
| Emd Serono, INC. | $1,239.32 | 2019-2025 | Mavenclad |
| Sk Life Science, INC. | $1,193.04 | 2020-2025 | |
| Ucb, INC. | $932.30 | 2019-2025 | Nayzilam, Briviact, Rystiggo |
| Jazz Pharmaceuticals INC. | $822.91 | 2019-2025 | Xywav, Epidiolex |
| Pfizer INC. | $769.35 | 2023-2025 | |
| Lilly USA, LLC | $734.57 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Lundbeck LLC | $706.33 | 2020-2025 | Vyepti, Rexulti |
| Neurelis, INC. | $647.58 | 2020-2025 | Valtoco |
| Genzyme Corporation | $567.37 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $550.81 | 2019-2025 | Hyqvia, Trintellix |
| Argenx US, INC. | $501.84 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Maquera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.